Dr. Lauri Burroughs
Claim this profileFred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Studies Aplastic Anemia
Studies Postprandial Fullness Syndrome
5 reported clinical trials
21 drugs studied
Area of expertise
1Aplastic Anemia
HLA positive
HLA-A positive
RB1 negative
2Postprandial Fullness Syndrome
SAMD9 positive
SAMD9L positive
GATA2 positive
Affiliated Hospitals
Clinical Trials Lauri Burroughs is currently running
Stem Cell Transplant Conditioning
for SCID
The investigators want to study if lower doses of chemotherapy will help babies with SCID to achieve good immunity with less short and long-term risks of complications after transplantation. This trial identifies babies with types of immune deficiencies that are most likely to succeed with this approach and offers them transplant early in life before they get severe infections or later if their infections are under control. It includes only patients receiving unrelated or mismatched related donor transplants. The study will test if patients receiving transplant using either a low dose busulfan or a medium dose busulfan will have immune recovery of both T and B cells, measured by the ability to respond to immunizations after transplant. The exact regimen depends on the subtype of SCID the patient has. Donors used for transplant must be unrelated or half-matched related (haploidentical) donors, and peripheral blood stem cells must be used. To minimize the chance of graft-versus-host disease (GVHD), the stem cells will have most, but not all, of the T cells removed, using a newer, experimental approach of a well-established technology. Once the stem cell transplant is completed, patients will be followed for 3 years. Approximately 9-18 months after the transplant, vaccinations will be administered, and a blood test measuring whether your child's body has responded to the vaccine will be collected.
Recruiting1 award Phase 244 criteria
Stem Cell Transplant with Conditioning Regimen
for Blood Diseases
This phase II clinical trial studies how well treosulfan, thiotepa, fludarabine, and rabbit anti-thymocyte globulin (rATG) before donor stem cell transplantation works in treating patients with nonmalignant (non-cancerous) diseases. Hematopoietic cell transplantation has been shown to be curative for many patients with nonmalignant (non-cancerous) diseases such as primary immunodeficiency disorders, immune dysregulatory disorders, hemophagocytic lymphohistiocytosis, bone marrow failure syndromes, and hemoglobinopathies. Powerful chemotherapy drugs are often used to condition the patient before infusion of the new healthy donor cells. The purpose of the conditioning therapy is to destroy the patient's abnormal bone marrow which doesn't work properly in order to make way for the new healthy donor cells which functions normally. Although effective in curing the patient's disease, many hematopoietic cell transplantation regimens use intensive chemotherapy which can be quite toxic, have significant side effects, and can potentially be life-threatening. Investigators are investigating whether a new conditioning regimen that uses less intensive drugs (treosulfan, thiotepa, and fludarabine phosphate) results in new blood-forming cells (engraftment) of the new donor cells without increased toxicities in patients with nonmalignant (non-cancerous) diseases.
Recruiting1 award Phase 28 criteria
More about Lauri Burroughs
Clinical Trial Related6 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Lauri Burroughs has experience with
- Fludarabine
- Treosulfan
- Allogeneic Hematopoietic Stem Cell Transplantation
- Fludarabine Phosphate
- Rabbit Anti-Thymocyte Globulin
- Thiotepa
Breakdown of trials Lauri Burroughs has run
Aplastic Anemia
Postprandial Fullness Syndrome
Anemia
Dyskeratosis Congenita
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Lauri Burroughs specialize in?
Lauri Burroughs focuses on Aplastic Anemia and Postprandial Fullness Syndrome. In particular, much of their work with Aplastic Anemia has involved HLA positive patients, or patients who are HLA-A positive.
Is Lauri Burroughs currently recruiting for clinical trials?
Yes, Lauri Burroughs is currently recruiting for 2 clinical trials in Seattle Washington. If you're interested in participating, you should apply.
Are there any treatments that Lauri Burroughs has studied deeply?
Yes, Lauri Burroughs has studied treatments such as Fludarabine, Treosulfan, Allogeneic Hematopoietic Stem Cell Transplantation.
What is the best way to schedule an appointment with Lauri Burroughs?
Apply for one of the trials that Lauri Burroughs is conducting.
What is the office address of Lauri Burroughs?
The office of Lauri Burroughs is located at: Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington 98109 United States. This is the address for their practice at the Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.